Amylyx Pharmaceuticals, Inc. (AMLX) vs Liquidia Corporation (LQDA)
- Amylyx Pharmaceuticals, Inc. AMLX 26.34 −4.74%
- Liquidia Corporation LQDA 34.35 −1.24%
Amylyx Pharmaceuticals, Inc. and Liquidia Corporation are both Drug Manufacturers Specialty & Generic companies. Amylyx Pharmaceuticals, Inc. is the larger, with a market value of $3.5B against $3.1B — 1.1× the size. Amylyx Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Liquidia Corporation trades at 21.9×. Liquidia Corporation grew revenue faster over the last twelve months: 2,233.7% against −77.1%. Liquidia Corporation has the higher net margin (30.7% vs 0.00%) and the higher return on invested capital (121.1% vs 0.00%). Across the 17 metrics below, Liquidia Corporation leads on 13 and Amylyx Pharmaceuticals, Inc. on 4.
Valuation
Profitability
| Metric | AMLX | LQDA | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | (42.65%) | 92.54% | 53.94% |
| Operating margin | 0.00% | 37.39% | 0.00% |
| Net margin | 0.00% | 30.74% | 0.00% |
| Free cash flow margin | 0.00% | 33.42% | 0.00% |
| Return on equity | (74.73%) | 131.82% | (0.40%) |
| Return on assets | (66.25%) | 35.57% | (3.32%) |
| Return on invested capital | 0.00% | 121.05% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack